Home » Stocks » Immunome

Immunome, Inc. (IMNM)

Stock Price: $12.15 USD -0.40 (-3.19%)
Updated Oct 21, 2020 4:00 PM EDT - Market closed
After-hours: $12.01 -0.14 (-1.15%) Oct 21, 4:06 PM

Stock Price Chart

Key Info

Market Cap 121.94M
Revenue (ttm) n/a
Net Income (ttm) -11.05M
Shares Out 9.28M
EPS (ttm) -1.19
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 21, 2020
Last Price $12.15
Previous Close $12.55
Change ($) -0.40
Change (%) -3.19%
Day's Open 12.55
Day's Range 12.00 - 12.68
Day's Volume 21,262
52-Week Range 11.54 - 16.77

More Stats

Market Cap 121.94M
Enterprise Value 112.80M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 9.28M
Float 9.42M
EPS (basic) n/a
EPS (diluted) -1.19
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short n/a
Short Ratio n/a
Short % of Float n/a
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 15.20
Revenue n/a
Operating Income n/a
Net Income -11.05M
Free Cash Flow n/a
Net Cash 9.14M
Net Cash / Share 0.91
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA n/a
ROE n/a
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

*No analysts have provided price targets for this stock.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-10.35-7.74
Net Income-10.44-7.85
Shares Outstanding6.566.52
Earnings Per Share-1.59-1.20
Operating Cash Flow-9.60-7.41
Capital Expenditures-0.23-0.23
Free Cash Flow-9.83-7.63
Cash & Equivalents2.641.70
Total Debt0.561.18
Net Cash / Debt2.080.53
Book Value-35.63-25.21
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Immunome, Inc.
Country United States
Employees 21
CEO Purnanand D. Sarma

Stock Information

Ticker Symbol IMNM
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: IMNM
IPO Date October 2, 2020


Immunome, a biotechnology company, discovers, develops, and commercializes highly targeted and native human cancer antibodies against universal cancer antigens. Its RealMAb technology enables the discovery of novel antigens and the cognate native human antibodies that target antigens; and ScreenMab multiplex functional screening technology identifies monoclonal antibodies that have exquisite for tumor neoantigens. The company was founded in 2006 and is based in Exton, Pennsylvania.